Royalty Pharma plc and Royalty Pharma Finance Corporation, 66214 [2022-23788]
Download as PDF
<![CDATA[
66214
Federal Register / Vol. 87, No. 211 / Wednesday, November 2, 2022 / Notices
2022. No more than three minutes shall
be allotted to each speaker. The time
allotted to each speaker will be
determined after registration closes.
Registration for the public comment
period, either in person or via
teleconference, will end on November 8
at noon ET. Participation in the public
comment period is governed by 39 CFR
232.1(n).
CONTACT PERSON FOR MORE INFORMATION:
Michael J. Elston, Secretary of the Board
of Governors, U.S. Postal Service, 475
L’Enfant Plaza SW, Washington, DC
20260–1000. Telephone: (202) 268–
4800.
Michael J. Elston,
Secretary.
[FR Doc. 2022–23895 Filed 10–31–22; 11:15 am]
BILLING CODE 7710–12–P
POSTAL SERVICE
Product Change—Priority Mail
Express, Priority Mail, First-Class
Package Service, and Parcel Select
Service Negotiated Service Agreement
AGENCY:
ACTION:
Postal ServiceTM.
Notice.
The Postal Service gives
notice of filing a request with the Postal
Regulatory Commission to add a
domestic shipping services contract to
the list of Negotiated Service
Agreements in the Mail Classification
Schedule’s Competitive Products List.
SUMMARY:
Date of required notice:
November 2, 2022.
DATES:
FOR FURTHER INFORMATION CONTACT:
Sean Robinson, 202–268–8405.
The
United States Postal Service® hereby
gives notice that, pursuant to 39 U.S.C.
3642 and 3632(b)(3), on October 26,
2022, it filed with the Postal Regulatory
Commission a USPS Request to Add
Priority Mail Express, Priority Mail,
First-Class Package Service, and Parcel
Select Service Contract 74 to
Competitive Product List. Documents
are available at www.prc.gov, Docket
Nos. MC2023–27, CP2023–26.
khammond on DSKJM1Z7X2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
Sarah Sullivan,
Attorney, Ethics & Legal Compliance.
[FR Doc. 2022–23851 Filed 11–1–22; 8:45 am]
BILLING CODE 7710–12–P
VerDate Sep<11>2014
16:38 Nov 01, 2022
Jkt 259001
SECURITIES AND EXCHANGE
COMMISSION
[Investment Company Act Release No.
34741; File No. 812–15386]
Royalty Pharma plc and Royalty
Pharma Finance Corporation
October 27, 2022.
Securities and Exchange
Commission (‘‘Commission’’ or ‘‘SEC’’).
ACTION: Notice.
AGENCY:
Notice of an application under section
6(c) of the Investment Company Act of
1940 (‘‘Act’’) for an exemption from all
provisions of the Act.
SUMMARY OF APPLICATION: Applicants
request an order that would permit
Royalty Pharma Finance Corporation
(‘‘FinCo’’) to issue and sell commercial
paper, preferred stock and other debt
securities to finance the operations of
Royalty Pharma plc (‘‘RP’’) and its
subsidiaries. Applicants state that FinCo
would qualify for the exemption
provided by rule 3a–5 under the Act but
for the facts that: (i) FinCo may finance
various subsidiaries of RP that are not
‘‘companies controlled by’’ RP within
the meaning of rule 3a–5 due to their
reliance on sections 3(c)(5) or 3(c)(6) of
the Act, (ii) FinCo is a direct subsidiary
of Royalty Pharma Holdings Ltd., a
wholly-owned subsidiary of RP, which
would not be a ‘‘company controlled by
the parent company’’ within the
meaning of rule 3a–5 to the extent it
relies on section 3(c)(6) of the Act, and
(iii) FinCo’s ‘‘parent company’’ for
purposes of rule 3a–5 would be RP,
which would not be a ‘‘parent
company’’ within the meaning of rule
3a–5 to the extent it relies on section
3(c)(6) of the Act.
APPLICANTS: Royalty Pharma plc and
Royalty Pharma Finance Corporation.
FILING DATE: The application was filed
on September 20, 2022.
HEARING OR NOTIFICATION OF HEARING:
An order granting the requested relief
will be issued unless the Commission
orders a hearing. Interested persons may
request a hearing on any application by
emailing the SEC’s Secretary at
Secretarys-Office@sec.gov and serving
the Applicants with a copy of the
request by email, if an email address is
listed for the relevant Applicant below,
or personally or by mail, if a physical
address is listed for the relevant
Applicant below. Hearing requests
should be received by the Commission
by 5:30 p.m. on November 21, 2022, and
should be accompanied by proof of
service on applicants, in the form of an
affidavit or, for lawyers, a certificate of
service. Pursuant to rule 0–5 under the
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
Act, hearing requests should state the
nature of the writer’s interest, any facts
bearing upon the desirability of a
hearing on the matter, the reason for the
request, and the issues contested.
Persons who wish to be notified of a
hearing may request notification by
emailing the Commission’s Secretary at
Secretarys-Office@sec.gov.
ADDRESSES: The Commission:
Secretarys-Office@sec.gov. Applicants:
Gregory S. Rowland, gregory.rowland@
davispolk.com.
FOR FURTHER INFORMATION CONTACT:
Steven I. Amchan, Senior Counsel, or
Lisa Reid Ragen, Branch Chief, at (202)
551–6825 (Division of Investment
Management, Chief Counsel’s Office).
SUPPLEMENTARY INFORMATION: For
Applicants’ representations, legal
analysis, and conditions, please refer to
Applicants’ application, dated
September 20, 2022, which may be
obtained via the Commission’s website
by searching for the file number at the
top of this document, or for an
Applicant using the Company name
search field, on the SEC’s EDGAR
system. The SEC’s EDGAR system may
be searched at, at https://www.sec.gov/
edgar/searchedgar/legacy/
companysearch.html. You may also call
the SEC’s Public Reference Room at
(202) 551–8090.
For the Commission, by the Division of
Investment Management, under delegated
authority.
J. Matthew DeLesDernier,
Deputy Secretary.
[FR Doc. 2022–23788 Filed 11–1–22; 8:45 am]
BILLING CODE 8011–01–P
SECURITIES AND EXCHANGE
COMMISSION
[Release No. 34–96164; File No. SR–MIAX–
2022–39]
Self-Regulatory Organizations: Notice
of Filing and Immediate Effectiveness
of a Proposed Rule Change by Miami
International Securities Exchange, LLC
To Amend Exchange Rule 1801,
Definitions and Rule 1809, Terms of
Index Options Contracts To Remove
References to BRIXX Indexes
October 27, 2022.
Pursuant to the provisions of Section
19(b)(1) of the Securities Exchange Act
of 1934 (‘‘Act’’) 1 and Rule 19b–4
thereunder,2 notice is hereby given that
on October 24, 2022, Miami
International Securities Exchange, LLC
(‘‘MIAX Options’’ or the ‘‘Exchange’’)
1 15
2 17
U.S.C. 78s(b)(1).
CFR 240.19b–4.
E:\FR\FM\02NON1.SGM
02NON1
]]>Agencies
[Federal Register Volume 87, Number 211 (Wednesday, November 2, 2022)]
[Notices]
[Page 66214]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23788]
=======================================================================
-----------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
[Investment Company Act Release No. 34741; File No. 812-15386]
Royalty Pharma plc and Royalty Pharma Finance Corporation
October 27, 2022.
AGENCY: Securities and Exchange Commission (``Commission'' or ``SEC'').
ACTION: Notice.
-----------------------------------------------------------------------
Notice of an application under section 6(c) of the Investment
Company Act of 1940 (``Act'') for an exemption from all provisions of
the Act.
Summary of Application: Applicants request an order that would permit
Royalty Pharma Finance Corporation (``FinCo'') to issue and sell
commercial paper, preferred stock and other debt securities to finance
the operations of Royalty Pharma plc (``RP'') and its subsidiaries.
Applicants state that FinCo would qualify for the exemption provided by
rule 3a-5 under the Act but for the facts that: (i) FinCo may finance
various subsidiaries of RP that are not ``companies controlled by'' RP
within the meaning of rule 3a-5 due to their reliance on sections
3(c)(5) or 3(c)(6) of the Act, (ii) FinCo is a direct subsidiary of
Royalty Pharma Holdings Ltd., a wholly-owned subsidiary of RP, which
would not be a ``company controlled by the parent company'' within the
meaning of rule 3a-5 to the extent it relies on section 3(c)(6) of the
Act, and (iii) FinCo's ``parent company'' for purposes of rule 3a-5
would be RP, which would not be a ``parent company'' within the meaning
of rule 3a-5 to the extent it relies on section 3(c)(6) of the Act.
Applicants: Royalty Pharma plc and Royalty Pharma Finance Corporation.
Filing Date: The application was filed on September 20, 2022.
Hearing or Notification of Hearing: An order granting the requested
relief will be issued unless the Commission orders a hearing.
Interested persons may request a hearing on any application by emailing
the SEC's Secretary at [email protected] and serving the
Applicants with a copy of the request by email, if an email address is
listed for the relevant Applicant below, or personally or by mail, if a
physical address is listed for the relevant Applicant below. Hearing
requests should be received by the Commission by 5:30 p.m. on November
21, 2022, and should be accompanied by proof of service on applicants,
in the form of an affidavit or, for lawyers, a certificate of service.
Pursuant to rule 0-5 under the Act, hearing requests should state the
nature of the writer's interest, any facts bearing upon the
desirability of a hearing on the matter, the reason for the request,
and the issues contested. Persons who wish to be notified of a hearing
may request notification by emailing the Commission's Secretary at
[email protected].
ADDRESSES: The Commission: [email protected]. Applicants:
Gregory S. Rowland, [email protected].
FOR FURTHER INFORMATION CONTACT: Steven I. Amchan, Senior Counsel, or
Lisa Reid Ragen, Branch Chief, at (202) 551-6825 (Division of
Investment Management, Chief Counsel's Office).
SUPPLEMENTARY INFORMATION: For Applicants' representations, legal
analysis, and conditions, please refer to Applicants' application,
dated September 20, 2022, which may be obtained via the Commission's
website by searching for the file number at the top of this document,
or for an Applicant using the Company name search field, on the SEC's
EDGAR system. The SEC's EDGAR system may be searched at, at https://www.sec.gov/edgar/searchedgar/legacy/companysearch.html. You may also
call the SEC's Public Reference Room at (202) 551-8090.
For the Commission, by the Division of Investment Management,
under delegated authority.
J. Matthew DeLesDernier,
Deputy Secretary.
[FR Doc. 2022-23788 Filed 11-1-22; 8:45 am]
BILLING CODE 8011-01-P
